HighLife
Development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | N/A | Series C | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
HighLife SAS is a medtech company specializing in the development of a unique transcatheter mitral valve replacement (TMVR) system designed to treat patients suffering from mitral regurgitation. The company's core product, the HighLife Mitral Valve Replacement System, consists of a valve prosthesis and a ring-shaped Sub Annular Implant (SAI). This system is engineered to self-center and align itself upon delivery, ensuring an easy and safe implantation process. HighLife's TMVR system is versatile, covering a wide range of mitral valve regurgitation patients with its adaptable design, suitable for native annuli with a largest axis ranging from 35 mm to 50 mm.
HighLife operates in the medical technology market, primarily serving healthcare providers and patients in need of advanced cardiac care solutions. The company's business model revolves around the development and eventual commercialization of its TMVR system, aiming to generate revenue through product sales and potentially licensing agreements once regulatory approvals are obtained.
Keywords: TMVR, mitral regurgitation, medtech, valve prosthesis, Sub Annular Implant, self-centering, self-aligning, cardiac care, healthcare providers, investigational device.